Understanding the immune system and metabolism in patients with acute leukemia
Official title: Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06814444 · Data updated 2026-11-12
This study looks at how the immune system and metabolism change in people with acute leukemia before and after treatment to see how these changes affect their response to therapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 170 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bologna, Bologna) |
| Status | Recruiting |
| Started | November 11, 2023 |
| Main results expected | December 11, 2029 |
| Study ends | December 11, 2030 |
| Registry record updated | February 7, 2025 |
| Trial ID | NCT06814444 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have been diagnosed with acute leukemia and are eligible for treatment involving chemotherapy or innovative therapies.
✕Probably not a fit
Patients who do not have a diagnosis of acute leukemia or are not eligible for any treatment schemes will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to characterize the immunophenotypic and immunometabolic profiles of patients diagnosed with acute leukemia, both before and after therapy. It will assess the relationship between the molecular and metabolic characteristics of leukemia cells and the surrounding immune system, identifying immune-modulatory mechanisms activated by malignant cells. Additionally, the study will explore how immunometabolic signatures correlate with therapy responses and investigate the role of extracellular vesicles in regulating immune cell metabolism. Samples will be collected from patients and healthy controls during routine care visits.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of how the immune system interacts with leukemia, potentially leading to improved treatment strategies.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in understanding the immune response in cancer, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: PATIENT * Diagnosis of Acute Leukaemia. * Eligibility for a treatment scheme involving either conventional chemotherapy or innovative therapies, such as monoclonal antibodies, molecular therapies with specific targets, metabolic and immunological therapies. * age ≥ 18 years. * Signature of informed consent by patients at the time of diagnosis. Healthy donors (AIL BOLOGNA ODV volunteers) * age ≥ 18 years. * Signature of informed consent. Exclusion Criteria: * no one
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy Recruiting
Study contacts
- Principal investigator: Antonio Curti, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Antonio Curti, MD
- Email: antonio.curti2@unibo.it
- Phone: +39 0512144074
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Menin inhibitors in pediatric relapsed or refractory acute leukemia
This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.
-
Artistic and movement activities to help anxiety in kids with ALL
Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.
-
Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma
Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.
-
QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers
This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.
-
Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers
This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.
-
Menin inhibitor maintenance after allogeneic stem cell transplant
This project will try menin inhibitor maintenance to see if it helps people with acute leukemia after allogeneic stem cell transplant who have KMT2A or related gene changes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.